BioVaxys and WuXi to Collaborate on SARS-CoV-2 S-Protein Production

News
Article

WuXi will produce SARS-CoV-2 s-proteins for BioVaxys’ COVID-19 vaccine candidate, BVX-0320, and for its Covid-T immunodiagnostic program.

BioVaxys Technology, a Canadian clinical-stage biopharmaceutical company, announced on March 15, 2021 that it has entered into an agreement with WuXi Biologics, the contract development and manufacturing organization business unit of Wuxi AppTec, to produce SARS-CoV-2 s-proteins for BioVaxys’ COVID-19 vaccine candidate, BVX-0320, and for its Covid-T immunodiagnostic program.

Under the terms of the agreement, WuXi will produce high yields of fully characterized SARS-CoV-2 s-protein for BioVaxys’ preclinical safety study of its Covid-T diagnostic, BioVaxys said in a company press release. The recombinant s-protein will be created and expressed using WuXi Biologics’ proprietary vector, allowing BioVaxys to secure the level of purity, consistency, and protein characterization expected by FDA.

The s-protein will also be used in BVX-0320, which is being prepared for a clinical study this year.

“Establishing a bioproduction method for a steady supply of purified and fully characterized s-protein from a validated process will enable us to quickly transition from having the GLP material for the upcoming Covid-T animal toxicity study to having a steady source [of] the GMP-grade s-protein for clinical trials later this year,” said Ken Kovan, BioVaxys president and chief operating officer, in the press release. “Now that we know the gene sequences, a further major benefit of our relationship with WuXi will be our ability to quickly source the s-protein of newly emerging SARS-CoV-2 variants for use in a planned multi-valent version of BVX-0320 and line extensions of Covid-T.”

Source: BioVaxys

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content